Introducing a start-up that creates lasting value for your R&D focused on in silico and in vitro humanized oral mucosa platforms because patient's safety is paramout.
WHAT WE DO
Offer R&D toxicity screening and AI-powered predictive services for Oral Care Products, Dental Devices, Pharma, Biotech & Nutraceutical Industries, within the scope of New Approach Methodologies (NAMs) and focused on Oral Toxicology and Oral Disease Modeling.
OUR MISSION & WHAT MAKES OUR COMPANY UNIQUE
To partner with leading organizations across Asia and beyond in transforming R&D into AI-powered, customer-centric, NAM-based workflows that accelerate preclinical research in Oral Toxicology.
PLEASE HELP US FILL OUT THIS SURVEY TO ACCELERATE CURRENT MARKET R&D FOR ORAL HEALTH CARE PRODUCTS:
4 STEPS TO ACCELERATE YOUR R&D
Step 1. Check and select your preferred R&D partner(s) and platform(s) from our list below, scroll down and write their names in our Request Form
Step 2. Tell us your preclinical R&D needs by describing your preferred oral toxicology or oral disease NAMs model in our Request Form
Step 3. After filling out all your choices in the form, just hit "SUBMIT THE FORM", and 24-48 hours later, we will send you a comprehensive work plan to accelerate your R&D into humanized NAMs
Step 4. After form submission, if you prefer to have it fully customized to your R&D needs, please scroll down to contact one of our Liaisons
FOLLOW THE 4 STEPS BELOW TO ACCELERATE YOUR R&D:
STEP 1: Choose your R&D AI-powered technology platform & service partner
STEP 2: Fill out this Request Form with all your information & hit submit
Organ-on-chips/MPS
Our R&D partners can work with several MPS combining tissue models with host-pathogen interactions. Context of Use (CoU): Xerostomia/Dry Mouth, Dry-eye Disease, Oral Mucositis. Target tissues: Oral mucosa, Salivary Glands
Organoids & 3D Tissue Equivalents
Readily bioassembled with magnetic bioprinting or tissue-mimetic in-house manufactured hydrogels. Target/CoU: Oral Mucosa, Oral dryness/mucositis, Salivary Glands
Project Consultation for in vitro/in silico Predictive Analytics (ML/AI) & Customized Preclinical Models
2D, Spheroids & Tumoroids
Promptly manufactured overnight by various in-house 3D platforms at our Bioprinting Center. Target: any type of oral and craniofacial cells including cancer/immortalized cells
Preferred partners from industry-leading companies:
The NamsTek team is ready to accelerate your R&D
Product Manager
Dr. Jaggaiah (Jay) Gorantla | PhD Biochemistry
Liaison | MPS & Toxicology
Dr. Toan (Tuan) Phan | DDS, MSc PhD in Oral Biology
Liaison | Organoids, Spheroids, Assembloids
Dr. Yeo-Jun Yoon | PhD in Cell, Developmental & Cancer Biology
CEO & CTO
João (Joe) Ferreira | DDS MSc PhD in Oral Biology, Entrepreneurship in Life Sciences
Consultant | NAMS
Dr. Michael Phelan | MSc, PhD in Bioengineering | Founder & Principal Consultant at InnovApproach Consulting | Previous roles: Associate Director MPA Quality and Manufacturing for Integral Molecular | NIH predoc fellow | Doc specialist and app QC at Tekni-Plex, Inc.
Liaison | In-Silico Modeling & Predictive Toxicology
Dr. Chayada (Sandy) Piantham | DVM PhD in Bioinformatics & Computation
Senior Consultant | In vitro 3D Culture & Bioprinting
Dr. Glauco Souza | MBA, PhD in Physical Chemistry and Nanotechnology | Member of Board of Directors of SLAS and several companies and start-ups (Greiner Bio-One International, ChemoSen3D, Nano3D Biosciences)
Consultant | Bioengineering & Pharma
Dr. Pedro Baptista | PharmD, PhD in Biomedicine | Board Member of European Society for Artificial Organs (ESAO); Internal Scientific Advisory Board of IIS Aragon and iLITE French Consortium; Entrepreneur leading IIS Aragon spin-off company.
© NamsTek Limited. All rights reserved. Last update: 31.03.2026
HQ address: Unit B, 11/F, 23 Thomson Road, Wan Chai, Hong Kong SAR | Satellite Branches: Korea, Thailand, Vietnam